Home>Topics>>Pharmacyclics Is Ripe For A Major Correction
Pharmacyclics Is Ripe For A Major Correction
Healthcare Sector and Stocks Analysis from Seeking Alpha
Sat, 16 Feb 2013
By John Li : Since February 2012, Pharmacyclics' ( PCYC ) price had a run up of 232%. The company's incredible run up was fueled by ibrutinib's incredible Phase III data results, Johnson & Johnson's ( JNJ ) generous milestone payments, numerous analysts' "buy" recommendations, and ibrutinib's ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.